Meeting Report 27-29 October 2020
The overall goal of the meeting was to discuss recent changes in treatment regimens and diagnostics for drug-resistant TB and to determine how these impact on the definition of XDR-TB, with a view to revising this definition. The pre-existing definition of XDR-TB w...as formulated in 2006 at a meeting of the Global Taskforce on XDR-TB, convened by WHO, and has been in use for clinical and surveillance purposes, since this time.
more
his guidance provides interim guidance for the integration of SARS-CoV-2 and influenza virologic and genomic surveillance, from sentinel site case enrolment and sampling to the eventual sharing of the virus sequence data, a process known as end-to-end surveillance. This guidance builds on experience...s and lessons learned as countries adapted their influenza surveillance systems in the context of the COVID-19 pandemic and reviews new evidence to provide guidance on end-to-end surveillance. The guidance includes new algorithms and strategies to adapt sentinel systems to make them resilient and agile for addressing global and national surveillance needs for influenza and COVID-19.covid-
more
Overview:
- Part A is an introductory part which will give you background information about CBDRR in Myanmar. It has a small section about the importance of CBDRR in Myanmar, the stakeholders of CBDRR in Myanmar, as well as an overview about the challenges that are faced when implementing CBDRR... in Myanmar.
- Part B contains the instructions on how to conduct the 9-step process agreed upon and described in detail in the step-by-step methodology document. These nine (9) steps are considered the minimum required activities to be followed by all MRCS community based initiatives regardless of their budget or time frame.
- Part C includes all the implementation steps of CBDRR programs namely step 6 (Action Plan Development), and step 7 (Implementation of Action Plan).
- Part D includes all the steps that finalize a CBDRR program namely step 4 and step 8 (Baseline and Endline Study) as well as step 9 (Handover & Exit Strategy).
more
WHO’s total revenue in 2020 was US$ 4299 million and total expenses were US$ 3561 million, resulting in a surplus of US$ 824 million, which includes finance revenue (e.g. interest and investment income) of US$ 86 million, representing increases of 38% and 15% in revenue and expenses respectively. ...10. The financial statements report all the Organization’s revenue and expenses. The Organization’s operations are managed under three fund groups: (1) the General Fund, which supports the programme budget, (2) Member States – other, and (3) the Fiduciary Fund (Note 2.18 gives particulars of each of the funds). This segregation of resources facilitates clearer reporting of WHO’s revenues and expenses.
more
.This assessment was conducted using focus group discussion(FGD)with peopleliving with disabilities who were members of the Ethiopian National Association of the Deaf(Person with hearing impairment), Ethiopian National Association of the Deaf -Blind ( Person with hearing and visual impairment), Ethi...opian National Association of the Blind (Person with visual impairment), Ethiopian National Association of the Physically Handicapped (Person with physical impairment), Ethiopian National Association of Intellectual Disability (Person with intellectual disability). In total 152 people living with disabilities participated in the discussion groups.Results from the assessment were analysed based on themes and are presented by each group in the following report.
more
For health care providers.
Sub-Saharan Africa has the highest maternal mortality in the world. According to estimates by the United Nations Maternal Mortality Estimation Inter-Agency Group (UN MMEIG)1 in September 2017, while the African Region had recorded a significant decline in maternal mortali...ty rate (MMR) of 37.8% between 2000 and 2017, 66% of the 295 000 maternal deaths reported globally occurred in sub-Saharan Africa. The African Region is also noted to have an extremely high MMR, estimated at 542 per 100000 livebirths, with an average annual rate of reduction of 2.9%.
more
BMJ 2009; 338 doi: https://doi.org/10.1136/bmj.b158 (Published 05 February 2009)
Cite this as: BMJ 2009;338:b158
Correspondence to: A Burns alistair.burns@manchester.ac.uk
Using the WHO model list of essential medicines to update a national essential medicines list
Since 1977, WHO has been working with countries to design the package of essential medicines as an integral component of treatment within the continuum of care, developing and disseminating the Model List ...of Essential Medicines (Model List). WHO is committed to supporting Member States in sharing best practices in selecting
essential medicines, and in developing processes for the selection of medicines for national essential medicines lists (national EMLs, or NEMLs) consistent with the evidence-based methods used for updating the WHO Model List.
more
Rwanda Guidelines for variation to registered pharmaceutical products.
No publication year indicated.
This policy discussion paper is designed to give an overview of the legal and policy implications of the dealat the present time.This paper is not designed to be an exhaustive statement or exploration of all issues –rather, its purpose is to highlight the key policy and legal challenges which the ...EU-Turkey Deal has created at this early stage from the perspective of forced migrants.
more